Comparative Pharmacology
Head-to-head clinical analysis: ACALABRUTINIB versus IBRUTINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACALABRUTINIB versus IBRUTINIB.
ACALABRUTINIB vs IBRUTINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase. It forms a covalent bond with a cysteine residue in the active site, blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in BTK's active site, leading to irreversible inhibition. BTK is essential for B-cell receptor signaling and survival of malignant B cells. Inhibition of BTK blocks pathways that promote B-cell proliferation, migration, and adhesion.
100 mg orally every 12 hours.
Adults: 560 mg orally once daily (4 capsules of 140 mg each) for mantle cell lymphoma; 420 mg once daily (3 capsules of 140 mg) for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, or chronic graft-versus-host disease.
None Documented
None Documented
Clinical Note
moderateIbrutinib + Digoxin
"Ibrutinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateIbrutinib + Digitoxin
"Ibrutinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateIbrutinib + Deslanoside
"Ibrutinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateIbrutinib + Acetyldigitoxin
"Ibrutinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 1 hour. Clinical context: short half-life supports twice-daily dosing, but BTK occupancy remains >90% over 12 hours due to irreversible binding.
Terminal half-life is approximately 4-6 hours, supporting twice-daily dosing for sustained BTK inhibition.
Primarily hepatic metabolism (CYP3A4); fecal excretion accounts for approximately 86% (including 69% as metabolites, 17% as unchanged drug). Renal excretion is minimal (<1% unchanged).
Primarily fecal (80%) as metabolites, with renal excretion accounting for <10% (mostly as metabolites).
Category C
Category D/X
BTK Inhibitor
BTK Inhibitor